The effect of Pirfenidone on pulmonary function parameters in post recovery COVID-19 patients with pulmonary fibrosis compared to placebo in a Government Medical College, West Bengal




Pirfenidone, Post recovery patients of COVID-19, Lung Fibrosis


Introduction and Aim: The recent COVID 19 pandemic has created an unprecedented challenge to the entire global healthcare system by affecting many people worldwide. Post COVID complications are multi-systemic, but pulmonary post COVID complications are most common. Involvement of the lung parenchyma ultimately leads to pulmonary fibrosis in many of the patients. Pirfenidone is a widely used antifibrotic medication in the field of idiopathic pulmonary fibrosis (IPF) management. Our study has assessed the effect of Pirfenidone on spirometry parameters in post recovery COVID 19 patients with diagnosed pulmonary fibrosis as compared to those that received placebo.


Materials and Methods: After obtaining approval from Institutional Ethics Committee, 70 adult patients of COVID-19 with established pulmonary fibrosis in the post recovery phase were chosen and allocated into two groups by randomization in 1:1 ratio. All other factors remaining same, one group was administered the recommended dose of Pirfenidone and the other group received a placebo. Spirometry parameters such as FEV1, FEV1 /FVC ratio, FVC, PEFR of both the groups were recorded on Day 0 and Day 90 and compared using standard statistical tests.


Results: It was found that on Day 0, PFT parameters of the two groups was comparable (P value>0.05). PFT parameters of the group receiving Pirfenidone showed significant improvement on day 90 (P value<0.05). In addition, on day 90, the PFT parameters of the group receiving Pirfenidone showed significantly better values than the group receiving placebo, P value <0.05.


Conclusion: As there is a significant improvement in the PFT parameters of post recovery COVID-19 patients suffering from pulmonary fibrosis, we conclude that Pirfenidone is helpful to improve the pulmonary function parameters in post recovery COVID -19 patients with established lung fibrosis as compared to placebo.

Author Biographies

Tanmoy Banerjee

Department of Physiology, Barasat Government Medical College, North 24 Parganas, West Bengal, India

Maumita Das

Department of Physiology, Bankura Sammilani Medical College, Bankura, West Bengal, India

Krishnachura Mitra

Department of Physiology, NRS Medical College, Kolkata, West Bengal, India


Gentile, F., Aimo, A., Forfori, F., Catapano, G., Clemente, A., Cademartiri, F., et al., COVID-19 and risk of pulmonary fibrosis: The importance of planning ahead. Eur J Prev Cardiol 2020; 27:1442-1446. DOI:

Spagnolo, P., Balestro, E., Aliberti, S., Cocconcelli, E., Biondini, D., Casa, G.D., et al., Pulmonary fibrosis secondary to COVID-19: A call to arms? Lancet Respir Med 2020; 8: 750-752. DOI:

George, P.M., Wells, A.U., Jenkins, R.G. Pulmonary fibrosis, and COVID-19: The potential role for antifibrotic therapy. Lancet Respir Med 2020;8: 807-815. DOI:

Han, X., Fan, Y., Alwalid, O., Li, N., Jia, X., Yuan, M., et al., Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology 2021; 299: E177-186. DOI:

Wu, X., Liu, X., Zhou, Y., Yu, H., Li, R., Zhan, Q., et al., 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalization: A prospective study. Lancet Respir Med 2021; 9: 747-754. DOI:

Guler, SA., Ebner, L., Aubry-Beigelman, C., Bridevaux, P.O., Brutsche, M., Clarenbach, C., et al., Pulmonary function and radiological features 4 months after COVID-19: First results from the national perspective observational Swiss COVID-19 lung study. Eur Respir J 2021; 57: 2003690. DOI:

Chopra, V., Flanders, S.A., O’Malley, M., Malani, A.N., Prescott, H.C. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med 2021; 174: 576-578. DOI:

Logue, J.K., Franko, N.M., McCulloch, D.J., McDonald, D., Magedson, A., Wolf, C.R., et al., Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open 2021; 4: e210830. DOI:

COVID-19. Med Hypotheses. 2020; 144: 110005, doi: 10.1016/j. mehy.2020.110005. DOI:

Vasarmidi, E., Tsitoura, E., Spandidos, D.A., Nikolaos,T., Katerina, M., Antoniou. Pulmonay fibrosis in the aftermath of the COVID-19 era (Review). Exp Ther Med. 2020; 20(3): 2557-2560. doi: 10.3892/etm.2020.8980, indexed in Pubmed: 32765748. DOI:

Noble, P.W., Albera, C., Bradford, W.Z., Ulrich, C., Marilyn, K., Glassberg, D., et al., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet 2011; 377: 1760-1769. DOI:

King TE Jr, Bradford W.Z., Castro-Bernardini, S., Elizabeth, A., Fagan, I., Glaspole, M., et al., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092. DOI:

Behr, J., Prasse, A., Kreuter, M., Johow, J., Rabe, K.F., Bonella, F., et al., Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): A double-blind, randomized, placebo-controlled, phase 2b trial. Lancet Respir. Med. 2021; 9: 476-486.

Barton, L.M., Duval, E.J., Stroberg, E., Ghosh, S., Mukhopadhyay, S. COVID-19 autopsies, Oklahoma, USA. Am J Clin Pathol 2020; 153: 725-733. DOI:

ESBRIET (Pirfenidone) summary of product characteristics. Available online: product-information/esbriet-epar-product-information_en.pdf (accessed on 16 April 2021).




How to Cite

Banerjee T, Das M, Mitra K. The effect of Pirfenidone on pulmonary function parameters in post recovery COVID-19 patients with pulmonary fibrosis compared to placebo in a Government Medical College, West Bengal. Biomedicine [Internet]. 2022 Nov. 14 [cited 2022 Nov. 27];42(5):1005-7. Available from:



Original Research Articles

Plum Analytics